May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial ...
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The ...
May 15, 2019 — Renal artery denervation (RDN) was found to be safe when employed with pulmonary vein isolation (PVI) to ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including ...
May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...
May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD premarket approval (PMA) labeling for the treatment of cardiogenic shock. The expansion extends the duration of support for each pump from 6 days to 14 days.
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vein ...
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus statement reflecting a worldwide updated review of the indications, techniques and outcomes of catheter ablation of ventricular arrhythmias (VAs). The expert consensus statement was presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and management of arrhythmogenic cardiomyopathy (ACM), including findings on genetics and disease mechanisms. Recommendations included in the 2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy were presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), such ...
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their ...
May 13, 2019 – A first-in-human pilot study of Medtronic's investigational Extravascular Implantable Cardioverter ...
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce atrial ...